Legend Holdings and Kawin Technology-backed Sciwind topped up its coffers in a series C round to advance its metabolic disease drug pipeline.
Sciwind Biosciences, a China-based metabolic disease therapy developer backed by conglomerate Legend Holdings and pharmaceutical firm Kawin Technology, closed a $70m series C round on Tuesday. Venture capital group IDG Capital led the round and was joined by Lyfe Capital and Loyal Valley Capital. Founded in 2017, Sciwind is developoing specialised treatments for metabolic conditions…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.